Alice Goodman

Axitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

A phase II study of NKTR 102 suggest that this agent will find a role in the treatment of patients with heavily pretreated metastatic breast cancer whose disease is progressing.

High-dose radiation was no better than standard-dose radiation given concurrently with chemotherapy in extending survival of patients with advanced unresectable NSCLC.

Radium-223, an alpha-emitting radiopharmaceutical, has been shown to improve overall survival (OS) in men with metastatic castrationresistant prostate cancer (mCRPC) in an interim analysis of the ALSYMPCA trial.

The approval of trastuzumab, targeted directly to the human epidermal growth factor receptor (HER2)-positive, was a major advance in extending the lives of women with HER2-positive breast cancer.

A new study presented at the 2011 annual meeting of the American Society for Radiation Oncology (ASTRO) found that 97% of radiation oncology team members believe they have a responsibility to report near-misses and errors...

Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).

It may be possible to predict which women with HR+ invasive breast cancer will experience recurrence by using a series of gene expression profiles.

Patient advocacy and support groups for cancer patients come in all shapes and sizes. The list is long and encompasses many types of cancer, from the most common to the rare.